Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

disease awareness

Eli Lilly HQ

Lilly delays filing of Lantus rival on safety concerns

Concerns over changes in liver fat detected in phase III trials

- PMLiVE

Novo Nordisk’s oral GLP-1 analogue looks set for phase III

Semaglutide said to be one of the firm’s most promising prospects

Sanofi reception

Leaderless Sanofi sees strong growth

French firm confirms it will seek a new CEO this quarter

Roche Basel Switzerland

Fresh approval for Roche’s Lucentis as competition heats up

Approved for more diabetes-related eye complications

- PMLiVE

Novo Nordisk confirms public listing for IT unit

Will spin off its NNIT business as a separate company

- PMLiVE

Monica Seles to front Shire’s binge eating disorder campaign

Tennis star experienced condition at height of her success

- PMLiVE

Sanofi launches inhaled insulin in US

Partners with MannKind on only diabetes treatment of its kind

- PMLiVE

Lilly and Boehringer claim first place for diabetes combination

US FDA backs Glyxambi as first combination of SGLT2 inhibitor and DPP-4 inhibitor.

- PMLiVE

Biogen Idec enlists son of NFL star for MS campaign

Tyler Campbell’s own career was cut short by neurological disease

- PMLiVE

Charity calls for universal liver health screening in UK

British Liver Trust will screen MPs as part of Love Your Liver campaign

- PMLiVE

Charity launches #SmearForSmear campaign

Jo's Cervical Cancer Trust aims to raise awareness of cancer screening

- PMLiVE

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links